Company / Operating Cash Flow
Serina Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$18.0M
FY2025
5-year range
-$18.0M / -$2.5M
FY2021-FY2025
Trend
-625.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow changed -625% YoY in FY2025, a notable deviation from the 6-year average annual change of -91%.
Based on SEC 10-K filings.
-$18M in FY2025.
Declined from -$2M to -$18M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 625.2% year-over-year.
- Peak operating cash flow was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$18.0M | -625.2% |
| FY2024 | -$2.5M | +0.0% |
| FY2023 | -$2.5M | +58.3% |
| FY2022 | -$5.9M | +24.4% |
| FY2021 | -$7.9M | +22.7% |
| FY2020 | -$10.2M | -27.1% |
| FY2018 | -$8.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026